No Data
No Data
Non-Executive Director Increases Shareholding in CStone Pharma; Shares Surge 25%
Kenneth Walton Hitchner, a non-executive director at CStone Pharma (HKG:2616), increased his shareholding in the company by purchasing 2,219,500 shares in the open market from April 9 to April 19 at a
Changes in Hong Kong stocks | Cornerstone Pharmaceutical-B (02616) rose more than 26%, leading the innovative drug concept, ASCO catalyzes market conditions, institutions are optimistic about policy+health insurance marginal improvement
Zhitong Finance App learned that innovative drug concept stocks showed strong performance. As of press release, Cornerstone Pharmaceutical-B (02616) rose 26.14% to HK$1.11; Cansino Biotech (06185) rose 16.91% to HK$20.95; Gacos-B (01167) rose 14.2% to HK$1.93; Nuocheng Jianhua (09969) rose 12.31% to HK$5.2; Rongchang Biotech (09995) rose 10.2% to HK$30.8. According to the news, the research title of the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was on April 25
Changes in Hong Kong stocks 丨 Biotech stocks continue to strengthen, the cornerstone pharmaceutical industry rises nearly 23%
Glonghui, May 2 | Cornerstone Pharmaceuticals rose nearly 23%, Cansino Biotech rose nearly 14%, Lepu Biotech rose more than 10%, and Pharmaceutical Kangde rose nearly 8.5%.
Cornerstone Pharmaceutical-B (02616.HK): Non-executive director Kenneth Walton Hitchner III increased shareholding by 2,219,500 shares
Gelonghui May 2 | Cornerstone Pharmaceutical-B (02616.HK) announced that Mr. Kenneth Walton Hitchner III (“Mr. Hitchner”), a non-executive director of the company, increased his shareholding in the company. The company was informed by Mr. Hitchner that it used its own capital to purchase a total of 2,219,500 shares on the open market between April 9 and April 19, 2024, at an average purchase price of approximately HK$0.86. After the bank purchased the shares, Mr. Hitchner held a total of 2,613,500 shares, which is equivalent to
Cstone Pharmaceuticals' CEO Boosts Stakeholding
Cstone Pharmaceuticals' (HKG:2616) CEO Jianxin Yang bought around an additional 3.3 million shares on the market during the six months ended today, Monday, a same-day filing on the Hong Kong bourse sa
Cornerstone Pharmaceutical-B (02616.HK): CEO and Executive Director Yang Jianxin purchased 3.345 million additional shares of the company, with a total purchase of 7,529,500 shares
Gelonghui, April 29 | Cornerstone Pharmaceutical-B (02616.HK) announced that the company was informed by Yang Jianxin, CEO, R&D President and Executive Director, that it purchased a total of 3.345 million shares on the open market with its own capital about six months before the announcement date. Since Yang Jianxin became CEO in August 2022, he has purchased a total of 7,529,500 shares. The purchase price range is HKD0.82 to HKD4.60. After the share purchase, Yang Jianxin held a total of about 4.97% of the company's total issued share capital at the date of the announcement.
No Data